Silence Therapeutics (SLN)
NASDAQ:SLN
Want to see SLN full AI Analyst Report?
Top Page
Silence Therapeutics
(NASDAQ:SLN)
Select Model
Select Model
Rating:50Neutral
Price Target:
$6.50
▼(-13.68% Downside)
Action:Reiterated
Date:06/12/26
Overall score reflects weak financial fundamentals (heavy losses and ongoing cash burn) partially offset by a relatively strong, low-debt balance sheet. Technical signals are largely neutral, while traditional valuation is constrained by negative earnings. A notable positive corporate catalyst is encouraging Phase 1 divesiran data ahead of expected Phase 2 topline results.
Positive Factors
Low Financial Leverage
Very low debt reduces solvency and interest burden risk, giving management durable financial flexibility to fund multi-year RNAi R&D. For a development-stage biotech, limited leverage lowers bankruptcy risk and preserves optionality to pursue partnerships or staged financings without heavy fixed costs.
Negative Factors
Persistent Cash Burn
Sustained negative operating and free cash flow means the company must continually access external capital to advance trials. Ongoing burn erodes runway, forces dilution or asset sales, and creates execution risk if financing windows tighten or partner contributions do not materialize over the multi-year development cycle.
Read all positive and negative factors
Positive Factors
Negative Factors
Low Financial Leverage
Very low debt reduces solvency and interest burden risk, giving management durable financial flexibility to fund multi-year RNAi R&D. For a development-stage biotech, limited leverage lowers bankruptcy risk and preserves optionality to pursue partnerships or staged financings without heavy fixed costs.
Read all positive factors
Silence Therapeutics (SLN) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$316.00M
Dividend YieldN/A
Average Volume (3M)101.05K
Price to Earnings (P/E)―
Beta (1Y)1.47
Revenue GrowthN/A
EPS GrowthN/A
CountryUS
Employees116
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-4.32
Shares Outstanding47,234,610
10 Day Avg. Volume169,902
30 Day Avg. Volume101,050
Financial Highlights & Ratios
PEG Ratio0.16
Price to Book (P/B)4.61
Price to Sales (P/S)513.72
P/FCF Ratio-4.61
Enterprise Value/Market Cap1.01
Enterprise Value/Revenue347.69
Enterprise Value/Gross Profit523.42
Enterprise Value/Ebitda-4.10
Forecast
1Y Price Target
$42.33Price Target Upside462.20% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.54
Revenue Forecast (FY)$3.85M
Silence Therapeutics Business Overview & Revenue Model
Company Description
Silence Therapeutics plc is a London, UK-based biotechnology company specializing in the research and development of groundbreaking ribonucleic acid (RNA) therapeutics. Its therapeutic focus areas include hematological, cardiovascular, and various...
How the Company Makes Money
Silence Therapeutics primarily makes money through (1) collaboration and licensing arrangements with larger pharmaceutical/biotechnology companies and (2) funding related to its partnered R&D activities, with (3) potential future revenue from comm...
Silence Therapeutics Earnings Call Summary
Earnings Call Date:Feb 27, 2025
(Q4-2024)
| % Change Since: |
Next Earnings Date:Aug 06, 2026
Earnings Call Sentiment Neutral
The earnings call highlighted positive clinical trial results for zerlasiran and divesiran, revenue growth, and an extended cash runway. However, the termination of the Hansoh Pharma collaboration and the delay of the zerlasiran Phase 3 study due to the need for a partner were significant challenges mentioned.Positive Updates
Positive Results for Zerlasiran Phase 2 Study
The ALPACAR-360 Phase 2 study of zerlasiran in ASCVD patients with high Lp(a) delivered positive results, showing Lp(a) reductions exceeded 90% and were durable. The study was featured in a late-breaker at AHA and published in JAMA.
Negative Updates
Hansoh Pharma Collaboration Termination
Hansoh Pharma opted not to pursue further development under the collaboration, resulting in the company regaining rights to three undisclosed preclinical liver targets.
Read all updates
Q4-2024 Updates
Positive
Negative
Positive Results for Zerlasiran Phase 2 Study
The ALPACAR-360 Phase 2 study of zerlasiran in ASCVD patients with high Lp(a) delivered positive results, showing Lp(a) reductions exceeded 90% and were durable. The study was featured in a late-breaker at AHA and published in JAMA.
Read all positive updates
Company Guidance
During the call, Silence Therapeutics provided guidance on several key metrics for their future operations. The company reported $43.3 million in revenues for 2024, an increase from $31.6 million in 2023, largely due to collaboration arrangements. They ended 2024 with $147.3 million in cash, cash equivalents, and short-term investments. Silence announced they would only initiate the Phase 3 outcomes study for zerlasiran, their siRNA for high Lp(a), once a partner is secured, which extends their cash runway into 2027. Additionally, they are prioritizing investment in programs targeting rare conditions, like divesiran for polycythemia vera (PV), which has received orphan drug designation in both the EU and US. The company also plans to commence a Phase 1 study of SLN548 targeting complement factor B in the second half of 2025. Silence transitioned to a U.S. domestic issuer status, moving from IFRS to U.S. GAAP, which resulted in a net loss decrease to $45.3 million in 2024 from $54.2 million in 2023.Silence Therapeutics Financial Statement Overview
Summary
Income Statement
28
Negative
Balance Sheet
64
Positive
Cash Flow
34
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 921.49K | 559.00K | 43.26M | 25.38M | 17.65M | 12.41M |
| Gross Profit | 612.12K | 344.00K | 31.45M | 15.06M | 6.68M | 4.96M |
| EBITDA | -78.13M | -88.05M | -48.99M | -49.78M | -39.94M | -45.42M |
| Net Income | -85.17M | -88.61M | -45.31M | -43.27M | -41.03M | -39.41M |
Balance Sheet | ||||||
| Total Assets | 115.12M | 131.44M | 161.92M | 119.45M | 107.50M | 96.19M |
| Cash, Cash Equivalents and Short-Term Investments | 70.08M | 85.11M | 117.73M | 68.79M | 71.14M | 73.54M |
| Total Debt | 136.00K | 160.00K | 93.49K | 346.00K | 446.00K | 137.00K |
| Total Liabilities | 65.72M | 69.14M | 54.83M | 97.45M | 85.43M | 87.67M |
| Stockholders Equity | 49.40M | 62.30M | 107.10M | 21.99M | 22.07M | 8.53M |
Cash Flow | ||||||
| Free Cash Flow | -65.67M | -62.33M | -54.22M | -39.40M | -57.59M | 7.39M |
| Operating Cash Flow | -65.56M | -62.27M | -54.05M | -39.35M | -57.04M | 9.19M |
| Investing Cash Flow | 6.39M | -47.99M | -17.55M | 16.43M | -20.50M | 11.71M |
| Financing Cash Flow | 986.00 | 15.00K | 113.54M | 25.16M | 52.58M | 41.45M |
Silence Therapeutics Technical Analysis
Positive
7.53
Price Trends
6.77
Positive
6.12
Positive
6.06
Positive
Market Momentum
-0.04
Negative
56.04
Neutral
80.26
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SLN, the sentiment is Positive. The current price of 7.53 is above the 20-day moving average (MA) of 6.45, above the 50-day MA of 6.77, and above the 200-day MA of 6.06, indicating a bullish trend. The MACD of -0.04 indicates Negative momentum. The RSI at 56.04 is Neutral, neither overbought nor oversold. The STOCH value of 80.26 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SLN.
Silence Therapeutics Risk Analysis
Silence Therapeutics disclosed 61 risk factors in its most recent earnings report. Silence Therapeutics reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Silence Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
56 Neutral | $315.18M | 4.85 | 41.40% | ― | ― | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $316.00M | -3.88 | -107.19% | ― | ― | ― | |
49 Neutral | $234.23M | -2.17 | -2781.56% | ― | 289.94% | 16.60% | |
46 Neutral | $778.11M | ― | 87.31% | ― | ― | -1004.74% | |
41 Neutral | $175.84M | -6.57 | 21.05% | ― | ― | 43.38% |
* Healthcare Sector Average
SLN
Silence Therapeutics
7.00
1.94
38.34%
GALT
Galectin Therapeutics
2.62
1.13
75.84%
ABEO
Abeona Therapeutics
5.67
-0.29
-4.95%
HUMA
Humacyte
1.07
-1.34
-55.60%
VOR
Vor Biopharma
14.07
9.64
217.61%
Silence Therapeutics Corporate Events
Business Operations and StrategyProduct-Related Announcements
Silence Therapeutics Highlights Positive Divesiran Phase 1 SANRECO Data
Positive
Jun 11, 2026
On June 11, 2026, Silence Therapeutics reported follow-up and quality-of-life data from its Phase 1 SANRECO study of divesiran in 21 phlebotomy-dependent polycythemia vera patients, presented at the European Hematology Association 2026 congress. T...
Business Operations and StrategyPrivate Placements and FinancingRegulatory Filings and Compliance
Silence Therapeutics Establishes New At-The-Market Program
Neutral
May 18, 2026
On May 18, 2026, Silence Therapeutics entered a new Open Market Sale Agreement with Jefferies LLC, allowing the biotech group to sell American Depositary Shares from time to time in at-the-market offerings, replacing a prior 2021 agreement that wa...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.